Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China

doi:10.3748/wjg.v26.i30.4465

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 26, Issue 30

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9320)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series, Tables (1-5) series.

Item

Count

PDF

595

WORD

175

HTML

5638

Figures (1-6)

248

Tables (1-5)

162

Sum=6818

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

690

Download

1812

Sum=2502

Aug 14, 2020 (publication date) through Apr 27, 2024

Times Cited of This Article

Times Cited (33)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Aug 14, 2020; 26(30): 4465-4478
Published online Aug 14, 2020. doi: 10.3748/wjg.v26.i30.4465

Table 5 Multivariate analysis of the objective response rate and progression-free survival in patients with advanced hepatocellular carcinoma treated with lenvatinib

Clinical factors	Category	Analysis of ORR		Analysis of PFS
Clinical factors	Category	P value	OR, 95%CI	P value	HR, 95%CI
Age (yr)	< 58.8	0.489	0.978 (0.919-1.041)	0.010	0.959 (0.929-0.990)
Gender	Male	0.571	1.828 (0.227-14.724)	0.606	1.137 (0.698-1.850)
HBV infection	HBV	0.371	2.300 (0.370-14.290)	0.151	1.844 (0.799-4.257)
First-line therapy	Sorafenib	0.212	0.324 (0.055-1.901)	0.167	1.724 (0.796-3.734)
Extrahepatic spread	Without	0.604	0.600 (0.088-4.118)	0.443	0.675 (0.247-1.844)
Tumor occupation	< 50%	0.937	1.080 (0.162-7.178)	0.169	2.043 (0.738-5.654)
Portal vein thrombus	Without	0.987	0.985 (0.167-5.817)	0.037	0.381 (0.154-0.944)
History of TACE	With	0.396	2.229 (0.350-14.186)	0.776	0.875 (0.348-2.197)
Combination factors
ECOG-PS score	0	0.066	3.571 (0.876-14.564)	0.05	4.9 (0.998-24.193)
ALBI stage	1	0.651	-	0.462	0.574 (0.130-2.524)
Child-Pugh class	A	0.061	-	0.042	0.468 (0.225-0.973)
BCLC stage	B	0.487	1.593 (0.425-5.971)	0.031	0.465 (0.232-0.931)

ECOG: Eastern Cooperative Oncology Group; PS: Performance Status; ALBI grade: Albumin-bilirubin grade; BCLC: Barcelona Clinic Liver Cancer; TACE: Transarterial chemoembolization; HBV: Hepatitis B virus; HCV: Hepatitis C virus; EHS: Extrahepatic spread; ORR: Objective response rate; PFS: Progression-free survival; OR: Odds ratio; HR: Hazard ratio.

Citation: Wang DX, Yang X, Lin JZ, Bai Y, Long JY, Yang XB, Seery S, Zhao HT. Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China. World J Gastroenterol 2020; 26(30): 4465-4478
URL: https://www.wjgnet.com/1007-9327/full/v26/i30/4465.htm
DOI: https://dx.doi.org/10.3748/wjg.v26.i30.4465